Polymer conjugates of interferon-beta with enhanced biological potency

• US 9,125,880 B2
• Filed: 12/23/2003
• Issued: 09/08/2015
• Est. Priority Date: 12/26/2002
• Status: Expired due to Fees

• Current Assignee: Mountain View Pharmaceuticals, Inc.
• Original Assignee: Mountain View Pharmaceuticals, Inc.
• Inventors: Saifer, Mark G. P., Martinez, Alexa L., Williams, L. David, Sherman, Merry R.
• Primary Examiner(s): Landsman, Robert
• Assistant Examiner(s): Hissong, Bruce D
• Application Number:
  US10/743,068
• Publication Number:
  US 20040126361A1
• Time in Patent Office: 4,277 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 14/565 IFN-beta
• CPC Class Codes: G01N 2333/565 IFN-beta

Abstract

Methods are provided for the synthesis of polymer conjugates of cytokines and receptor-binding antagonists thereof, especially a non-glycosylated interferon-beta, which conjugates retain unusually high biological potency. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods. The conjugates of the present invention retain a high level of biological potency compared to those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines. In assays in vitro, the biological potency of the conjugates of non-glycosylated interferon-beta of the present invention is substantially higher than that of unconjugated interferon-beta and is similar to that of interferon-beta-1a that is glycosylated. The conjugates of the present invention also exhibit an extended half-life in vivo compared to the corresponding unconjugated cytokine. The present invention also provides kits comprising such conjugates and/or compositions, and methods of use of such conjugates and compositions in a variety of diagnostic, prophylactic and therapeutic applications, including treatment of multiple sclerosis.

Claims

1. A composition comprising a detergent and a non-glycosylated interferon-beta conjugate prepared by selectively coupling one or more synthetic water-soluble polymers to the amino-terminal amino acid of a non-glycosylated interferon-beta,

wherein said one or more synthetic water-soluble polymers is selected from the group consisting of one or more polyethylene glycols and one or more polyethylene oxides,

wherein said amino-terminal amino acid is located remotely from the receptor-binding domain(s) of said interferon-beta, and

wherein said conjugate has increased in vitro biological potency as compared to said non-glycosylated interferon-beta that has not been coupled with one or more synthetic water-soluble polymers when assayed under the same conditions.

2. The composition of claim 1, which is pharmaceutically acceptable.

23. The composition of claim 1, wherein the in vitro biological potency of said conjugate is measured in a cell-culture assay that responds to interferon-beta.

24. The composition of claim 23, wherein said assay is selected from the group consisting of an antiproliferative assay, an antiviral assay, a signal transduction assay and a gene activation assay.

25. The composition of claim 24, wherein said assay is an antiproliferative assay.

32. The composition of claim 1, wherein said detergent is sodium dodecyl sulfate (SDS).

35. A kit comprising the composition of claim 1.

37. A kit comprising the pharmaceutically acceptable composition of claim 2.

3. A composition comprising a detergent and a conjugate that comprises a non-glycosylated interferon-beta selectively and covalently coupled at its amino-terminal amino acid to one or more synthetic water-soluble polymers,

wherein said one or more synthetic water-soluble polymers is selected from the group consisting of one or more polyethylene glycols and one or more polyethylene oxides,

wherein said amino-terminal amino acid is located remotely from the receptor-binding domain(s) of said interferon-beta, and

wherein the in vitro biological potency of said interferon-beta is increased compared to the same interferon-beta that has not been so coupled when assayed under the same conditions.

5. The composition of claim 3 or claim 4, wherein said interferon-beta has the amino acid sequence of interferon-β

-1b specified in SEQ ID NO;

1.

6. The composition of claim 5, wherein the in vitro biological potency of said interferon-β

-1b is increased to approximately the in vitro potency of interferon-β

-1a, which interferon-β

-1a has the amino acid sequence specified in SEQ ID NO;

2 and is glycosylated on asparagine residue 80.

7. The composition of claim 3 or claim 4, wherein said polymer is selectively and covalently coupled to the alpha amino group of the amino-terminal amino acid of said interferon-beta.

8. The composition of claim 7, wherein said selective and covalent coupling of said polymer to said alpha amino group is via a secondary amine linkage.

9. The composition of claim 3 or claim 4, wherein said polymer is, or said polymers are, coupled to a chemically reactive side chain group of said amino-terminal amino acid.

10. The composition of claim 9, wherein said reactive side chain group is an aldehyde group that is introduced by selective oxidative cleavage of an amino-terminal serine or threonine residue of an interferon-beta.

11. The composition of claim 3 or claim 4, wherein said one or more water-soluble polymers is a polyalkylene glycol.

12. The composition of claim 11, wherein said one or more polyalkylene glycol(s) is selected from the group consisting of a poly(ethylene glycol), a mono-methoxypoly(ethylene glycol) and a monohydroxypoly(ethylene glycol).

13. The composition of claim 12, wherein said one or more polyalkylene glycol(s) is a monomethoxypoly(ethylene glycol).

14. The composition of claim 12, wherein said one or more polyalkylene glycol(s) is a monohydroxypoly(ethylene glycol).

15. The composition of claim 11, wherein said one or more polyalkylene glycol(s) has a molecular weight of between about 1 kDa and about 100 kDa, inclusive.

16. The composition of claim 15, wherein said one or more polyalkylene glycol(s) has a molecular weight of between about 8 kDa and about 14 kDa, inclusive.

17. The composition of claim 15, wherein said one or more polyalkylene glycol(s) has a molecular weight of between about 10 kDa and about 30 kDa, inclusive.

18. The composition of claim 17, wherein said one or more polyalkylene glycol(s) has a molecular weight of between about 18 kDa and about 22 kDa, inclusive.

19. The composition of claim 18, wherein said one or more polyalkylene glycol(s) has a molecular weight of about 20 kDa.

20. The composition of claim 15, wherein said one or more polyalkylene glycol(s) has a molecular weight of about 30 kDa.

21. The composition of claim 3 or claim 4, wherein the coupling of said one or more polymers to said interferon-beta at said amino-terminal amino acid pseudoglycosylates or pseudohyperglycosylates said interferon-beta.

22. The composition of claim 3 or claim 4, which is pharmaceutically acceptable.

26. The composition of claim 3, wherein the in vitro biological potency of said conjugate is measured in a cell-culture assay that responds to interferon-beta.

27. The composition of claim 26, wherein said assay is selected from the group consisting of an antiproliferative assay, an antiviral assay, a signal transduction assay and a gene activation assay.

28. The composition of claim 27, wherein said assay is an antiproliferative assay.

33. The composition of claim 3, wherein said detergent is sodium dodecyl sulfate (SDS).

36. A kit comprising the composition of claim 3 or claim 4.

38. A kit comprising the pharmaceutically acceptable composition of claim 22.

4. A composition comprising a detergent and a conjugate that comprises a non-glycosylated interferon-beta selectively and covalently coupled at its amino-terminal amino acid to one or more synthetic water-soluble polymers,

wherein said one or more synthetic water-soluble polymers is selected from the group consisting of one or more polyethylene glycols and one or more polyethylene oxides,

wherein said amino-terminal amino acid is located remotely from the receptor-binding domain(s) of said interferon-beta, and

wherein the in vitro biological potency of said conjugate of interferon-beta is increased compared to the same interferon-beta to which the same number of the same synthetic water-soluble polymers has been coupled randomly to solvent-accessible lysine residues when assayed under the same conditions.

29. The composition of claim 4, wherein the in vitro biological potency of said conjugate is measured in a cell-culture assay that responds to interferon-beta.

30. The composition of claim 29, wherein said assay is selected from the group consisting of an antiproliferative assay, an antiviral assay, a signal transduction assay and a gene activation assay.

31. The composition of claim 30, wherein said assay is an antiproliferative assay.

34. The composition of claim 4, wherein said detergent is sodium dodecyl sulfate (SDS).